Ron Cooper, enGene CEO
September 26, 2024 07:00 AM EDT
R&D
Cell/Gene Tx

En­Gene un­veils first set of piv­otal da­ta for NMIBC ther­a­py

Kyle LaHucik

Senior Reporter

A small US and Cana­di­an gene ther­a­py biotech has re­leased a look at da­ta from its ex­per­i­men­tal blad­der can­cer treat­ment, hop­ing to en­ter a field …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Roche, Genen­tech end an­ti-tau Alzheimer’s drug col­lab­o­ra­tion with UCB

No­vo de­clares Phase 3 car­diac out­comes tri­al win for oral GLP-1

Star­board takes ac­tivist stake in J&J con­sumer spin­out Ken­vue

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Aven­Cell gets $112M to build switch­able CAR-T ther­a­pies for ‘the last fron­tier’ of blood can­cers

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times